Send us Fan Mail

🧪 The EPOC Trial:

Compared FLOT chemotherapy alone vs chemo + radiation before surgery in localized esophageal/gastroesophageal adenocarcinoma.

📈 Findings:

FLOT alone led to better 3-year progression-free survival: 51.6% vs 35%.

No survival benefit from adding radiation.

Patients receiving FLOT alone had fewer complications, improved tolerance, and less treatment-related morbidity.

🧩 Clinical Takeaway:

For operable esophageal adenocarcinoma, skip the radiation if you're doing full-dose chemo.

Less burden for patients, especially elderly or frail.

Send us Fan Mail

🧠 Surprising contender:

OA is not just wear-and-tear — there's an inflammatory phenotype.

🧪 Trial:

MTX 10–25 mg/week in knee OA with persistent pain.

Significant ↓ pain and improved function vs placebo.

⚠️ Side Effects:

GI upset, mouth ulcers, fatigue.

Hepatotoxicity, myelosuppression, pulmonary fibrosis (rare).

Always co-prescribe folic acid.

🧩 Clinical Takeaway:

Consider in refractory OA when NSAIDs, injections, and PT have failed.

Especially useful when opioids are not an option.

Send us Fan Mail

🧠 Historical practice:

Pre-load clopidogrel (or ticagrelor) before cath.

Rationale: reduce thrombotic burden prior to PCI.

🧪 New Data:

Large observational study: 100k+ NSTEMI patients.

No benefit in MI or death with pretreatment.

Longer LOS, delayed CABG in pre-treated patients.

🧩 Clinical Takeaway:

Defer P2Y12 until coronary anatomy is known — especially if CABG is on the table.

If PCI is clearly planned and delay expected — preloading may still be reasonable.

Send us Fan Mail

🧠 Problem:

80% of menopausal women suffer from vasomotor symptoms (hot flashes, night sweats).

Many can't take hormone therapy (VTE, CAD, breast CA).

💊 Fezolinetant:

NK3 receptor antagonist — first in class.

Reduces frequency and intensity of hot flashes.

Safe in patients who can’t take estrogen.

⚠️ Side Effects:

GI symptoms, transaminitis.

Requires liver function monitoring.

🧩 Clinical Takeaway:

A breakthrough for non-hormonal menopause management.

Ideal for patients at high risk or contraindications to HRT.

Send us Fan Mail

🧠 Core Concept:

Cerebral perfusion pressure (CPP) = MAP – ICP.

Normal ICP = ~10 mmHg; threshold for concern >20 mmHg.

🧰 Management Strategies:

Elevate head of bed (30°), ensure neck is midline.

3% hypertonic saline preferred over mannitol in AKI.

Short-term hyperventilation (↓ PaCO₂ → vasoconstriction).

Consider sedation or decompressive craniectomy in refractory cases.

External ventricular drain (EVD) for CSF removal and monitoring.

🧩 Clinical Takeaway:

Managing ICP is about protecting perfusion.

Monitor trends closely — especially in trauma, hemorrhage, hepatic encephalopathy.

Send us Fan Mail

🧠 Context:

Rising rates of carbapenem-resistant gram-negatives, especially those producing MBLs like NDM, VIM.

💊 Drug Combo:

Aztreonam + Avibactam = a lifeline for metallo-beta-lactamase (MBL) producers.

FDA-approved for:

Complicated intra-abdominal infections (with metronidazole).

Hospital-acquired and ventilator-associated pneumonias (HAP/VAP).

🧩 Clinical Takeaway:

Reserved for pan-resistant infections; not a first-line agent.

ID consult required in most hospitals due to high cost and restricted use.

This is your last-resort ammo — know when to reach for it.

Send us Fan Mail

🧠 Background:

RSV causes significant morbidity/mortality in older adults.

Previously considered a pediatric virus only.

📈 Epidemiology:

Hospitalization rate:

91/100,000 (ages 64–74).

738/100,000 in assisted living patients.

💉 Vaccine Update:

CDC now recommends RSV vaccine for:

All ≥75 years old.

60–74 years with chronic conditions (lung, kidney, diabetes with organ damage).

Efficacy: 71–80%, wanes to ~50% by 19 months.

⚠️ Considerations:

Possible risk of Guillain-Barré — ongoing surveillance.

Only one dose needed (no boost from second shot yet).

🧩 Clinical Takeaway:

Strongly recommend for frail seniors and those in communal living.

Shared decision-making still advised for those age 60–74.

Send us Fan Mail

🧠 Clinical Context

We’ve long been taught to stop metformin once GFR drops below 30 due to concerns about lactic acidosis. But what if—just maybe—some patients might actually do better by continuing it? Enter a large-scale Scottish national database review that turned this dogma on its head.

🧪 Study Highlights

• Design: Retrospective analysis of a national database in Scotland
• Population: Patients with Stage 4 and 5 CKD (GFR <30 mL/min) who continued metformin for over 6 months despite guidelines
• Group Division:
  • Continued metformin past GFR <30
  • Stopped metformin upon reaching GFR <30

📈 Outcomes

• Mortality:
  • Patients who continued metformin had lower 3-year all-cause mortality compared to those who stopped
• Cause of Death:
  • Leading causes in both groups: cancer, respiratory disease, cardiovascular events
  • Interestingly, respiratory deaths were significantly lower in those who stayed on metformin
• CV Events: No significant difference in major adverse cardiovascular outcomes between the groups

⚠️ Caveats

• Not a randomized trial — many possible confounders
• Nearly half of those continuing metformin eventually stopped due to provider decision or follow-up
• Mechanism for fewer respiratory deaths is unknown — could be unrelated or due to unmeasured factors

🧩 Clinical Takeaway

This accidental natural experiment suggests we might be a bit too strict with our GFR <30 cutoff. While lactic acidosis risk is real, the data hints that patients with stable CKD might tolerate metformin better than previously thought.

💡 Time to rethink? Maybe. But we still need prospective trials to safely redraw the lines. For now, this is not a green light, but definitely a yellow one.

Data Source: Scottish National Database, observational cohort

Send us Fan Mail

🧠 Clinical Problem:

HFpEF (Heart Failure with Preserved EF) has lacked effective, proven therapies.

Finerenone (non-steroidal MRA) offers new hope.

🧪 FINEARTS-HF Trial:

6,000+ patients with EF ≥40%, followed for ~32 months.

Compared Finerenone vs placebo.

📈 Results:

↓ Heart failure hospitalization significantly.

No significant reduction in CV mortality.

Hyperkalemia: 9.7% (Finerenone) vs 4.2% (Placebo).

🧩 Clinical Takeaway:

May offer benefit for HFpEF — especially if SGLT2i also used.

Expensive; Spironolactone may be a lower-cost alternative with similar benefit.

Important addition to the limited HFpEF toolbox.

Send us Fan Mail

🧠 Clinical Context

Heart failure with preserved ejection fraction (HFpEF) typically presents with orthopnea, dyspnea, edema, and often subtle signs like an S3 or elevated JVP—despite a normal EF (>50%). Diagnosing it requires nuance, and ruling out other causes of dyspnea is key.

🧪 Rule Out First

Before calling it HFpEF, think differentials:

• Anemia
• Cirrhosis
• COPD exacerbation
• Renal failure
• NSAID-induced fluid overload
• Medication effects

Get a BNP (>100) or pro-BNP (>300), but remember these can be falsely low in obesity.

🔍 Look for Etiology

• Consider amyloidosis (found in 1 in 8 HFpEF cases)
• Assess for NSAID use, excessive dietary sodium/alcohol
• Be alert around holidays—fluid/salt overload is real!

🚩 Inciting Factors

• High-sodium and high-alcohol meals
• Holiday binges (Super Bowl, Christmas, Thanksgiving)
• Poor adherence to fluid restriction or diuretics

💊 Medications for HFpEF: Shelved Smartly

Top Shelf:

• SGLT2 Inhibitors (dapagliflozin, empagliflozin)
  • Class-wide effect
  • First-line for HFpEF with NYHA II–IV symptoms
• Finerenone
  • New on the scene
  • Especially promising in patients with diabetic kidney disease

Lower Shelf:

• Spironolactone
  • Evidence from the controversial TOPCAT trial
  • Use with caution; monitor K+ and renal function
• Sacubitril/Valsartan (ARNI)
  • Class IIb recommendation
  • Stronger benefit in women and men with EF <55–60%
  • Limited by high cost
• Candesartan
  • A viable option for those who can't afford ARNI
• Diuretics
  • Not disease-modifying but essential for symptom relief in volume-overloaded patients

⚠️ Clinical Considerations

• HFpEF is complex with limited effective therapies
• Many benefits are modest, but SGLT2 inhibitors stand out
• Etiology and lifestyle often drive exacerbations—address these too

🧩 Clinical Takeaway

Treating HFpEF is less about one miracle drug and more about combining modestly effective meds with personalized care. Always rule out other causes, explore etiologies like amyloidosis, and be mindful of inciting factors—especially around festive seasons.

SGLT2s lead the pharmacologic pack, but cost, side effects, and patient-specific factors still dictate the best plan. There's progress—but the heart of HFpEF still holds a few secrets.